Ornithine Aketoglutarate

Ornithine Aketoglutarate

SCHEMBL42530

NCCCC(N)C(=O)O.NCCC[C@H](N)C(=O)O

nearest known ligand 0.86

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSR P00390 2/20 0.86
ARG2 P78540 4/20 0.56
ARG1 P05089 3/20 0.56
CYP1A2 P05177 2/20 0.54
GRM8 O00222 1/20 0.54
GRM6 O15303 1/20 0.54
GRIN2D O15399 1/20 0.54
GRIN3B O60391 1/20 0.54
GRIK1 P39086 1/20 0.54
GRM5 P41594 1/20 0.54
GRIA1 P42261 1/20 0.54
GRIA2 P42262 1/20 0.54
GRIA3 P42263 1/20 0.54
SLC1A3 P43003 1/20 0.54
SLC1A2 P43004 1/20 0.54
SLC1A1 P43005 1/20 0.54
GRIA4 P48058 1/20 0.54
GRIN1 Q05586 1/20 0.54
GRIN2A Q12879 1/20 0.54
GRIK2 Q13002 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ornithine SCHEMBL30563013 1.00
D-Ornithine SCHEMBL1537220 1.00 GSR (0.86) GSRARG2ARG1CYP1A2GRM8
Ornithine SCHEMBL30695803 1.00
Ornithine SCHEMBL20362354 1.00
Ornithine Aketoglutarate SCHEMBL1326163 1.00 GSR (0.86) GSRARG2ARG1CYP1A2GRM8
D-Ornithine SCHEMBL43724 1.00
Ornithine SCHEMBL30695804 1.00
Ornithine Aketoglutarate SCHEMBL8578 1.00
Ornithine SCHEMBL624782 1.00 GSR (0.86) GSRARG2ARG1CYP1A2GRM8
Ornithine SCHEMBL8579 1.00

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110286915-A1 Nanocarriers for Drug Delivery THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-11-24 US claimed
EP-2344134-A2 NANOCARRIERS FOR DRUG DELIVERY The Regents of the University of California (US) 2011-07-20 EP claimed
US-8541184-B2 Screening for neurotoxic amino acid associated with neurological disorders THE INSTITUTE FOR ETHNOMEDICINE (US) 2013-09-24 US disclosed
EP-2449488-A1 METHOD FOR NORMALIZATION IN METABOLOMICS ANALYSIS METHODS WITH ENDOGENOUS REFERENCE METABOLITES BIOCRATES Life Sciences AG (AT) 2012-05-09 EP disclosed
EP-2430105-A1 AQUEOUS BINDER SYSTEM COMPRISING EPOXY-FUNCTIONAL AND CARBOXYL-FUNCTIONAL COMPONENTS, A PROCESS FOR THEIR MANUFACTURE, AND A METHOD OF USE THEREOF Cytec Austria GmbH (AT) 2012-03-21 EP disclosed
US-8119780-B2 Chitosan-derivative compounds and methods of controlling microbial populations SYNEDGEN, INC. (US) 2012-02-21 US disclosed
US-20120028927-A1 Novel Triazene Compounds For The Treatment Of Cancer TRIN THERAPEUTICS GMBH (DE) 2012-02-02 US disclosed
US-20110286921-A1 18F-LABELLED FOLATES AS PET RADIOTRACERS Merck & Cie (CH) 2011-11-24 US disclosed
US-20110286915-A1 Nanocarriers for Drug Delivery THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-11-24 US disclosed
EP-2387409-A1 CHITOSAN DERIVATIVES ALONE OR IN COMBINATION FOR THE TREATMENT OF MDR MICROBIAL INFECTIONS Synedgen, Inc. (US) 2011-11-23 EP disclosed
US-8038990-B2 Compositions and methods for the prevention and removal of biofilms on inert and biological surfaces THE OHIO STATE UNIVERSITY (US) 2011-10-18 US disclosed
WO-2011028967-A1 METHODS AND COMPOSITIONS FOR DISRUPTING BIOFILM UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS SYNEDGEN INC. (US) 2011-03-10 WO disclosed
US-7901895-B2 Screening environmental samples such as food, water for beta-N-methylamino-L-alanine (BMAA) associated with risk of nervous system disorders such as dementia, amyotrophic lateral sclerosis THE INSTITUTE FOR ETHNOMEDICINE (US) 2011-03-08 US disclosed
US-20110041210-A1 Plants Having Enhanced Yield-Related Traits and a Method for Making the Same BASF PLANT SCIENCE GMBH 2011-02-17 US disclosed
US-20110028596-A1 RUBBER COMPOSITION FOR COATING A STEEL WIRE MATERIAL THE YOKOHAMA RUBBER CO., LTD 2011-02-03 US disclosed
WO-2011000753-A1 METHOD FOR NORMALIZATION IN METABOLOMICS ANALYSIS METHODS WITH ENDOGENOUS REFERENCE METABOLITES BIOCRATES LIFE SCIENCES AG (AT) 2011-01-06 WO disclosed
EP-2268820-A1 PLANTS HAVING ENHANCED YIELD-RELATED TRAITS AND A METHOD FOR MAKING THE SAME BASF Plant Science GmbH (DE) 2011-01-05 EP disclosed
WO-1997016407-A1 BETA-AMINO ESTER COMPOUNDS OF PERFUME ALCOHOLS THE PROCTER & GAMBLE COMPANY (US) 1997-05-09 WO disclosed
EP-0771785-A1 Beta-amino ester compounds of perfume alcohols and their use in cleaning or laundry compositions THE PROCTER & GAMBLE COMPANY (US) 1997-05-07 EP disclosed
WO-1996023490-A9 FORMULATIONS AND METHODS FOR REDUCING SKIN IRRITATION 1996-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110286921-A1 18F-LABELLED FOLATES AS PET RADIOTRACERS FOLR1, FOLR2, SLC19A1 GSR 360/4885ARG2 1559/4885ARG1 1658/4885
US-20110286915-A1 Nanocarriers for Drug Delivery CLTA, EPCAM, EGFR GSR 1966/4885ARG2 2821/4885ARG1 3516/4885
US-20120028927-A1 Novel Triazene Compounds For The Treatment Of Cancer KRAS, TP53, VHL GSR 860/4885ARG2 2268/4885ARG1 3926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.